Gemzar "Double-Patenting" Case Has Broad Implications For Industry Pipeline
Executive Summary
Eli Lilly & Co. has the backing of the pharmaceutical and biotech industries in its effort to get an appeals court to reverse its ruling that the company’s Gemzar (gemcitabine) patent is invalid.